Search Engine for New Anti-Cancer Targets

  • Yeda
  • From Israel
  • Responsive
  • Patents for licensing

Summary of the technology

Many newly developed anti-cancer treatments rely on identifying cancer unique signatures that can be used to harness the immune system against the tumor. The internal state of all cells is constantly represented on their surfaces by unique molecules called Human Leukocyte Antigen (HLA) bound peptides. Consequently, many efforts focus on identifying cancer?unique HLA-bound peptides. However, currently available methods only allow considering the peptides’ primary sequence, overlooking other potential chemical modifications known as posttranslational modifications (PTMs). PTMs greatly affect the binding of these peptides to HLA molecules and thus the subsequent response by interacting immune cells. There is a need for a method to identify cancer-unique HLAbound peptides that takes into account the peptides’ PTMs. The group of Prof. Yifat Merbl successfully developed a computational platform; where an improved pipeline allows for simultaneous in?parallel detection of multiple PTMs, expanding the landscape of HLA bound-peptides by up to 20% by identifying chemically modified peptides.

Yeda

Background and Unmet Need

The internal state of cells is represented on their surfaces by Human Leukocyte Antigen (HLA), molecules that bind and display samples from the cells’ waste disposal system on the cell surface. These waste samples are short sections of different proteins from inside the cell, peptides, which are unique and specific to that cell. This is used by the immune system to check for any abnormalities in the cells. Consequently, HLA-bound peptides serve as the immune system’s window into the cellular proteome and, as such, are key components of immune system defenses. HLA-bound peptides that are unique to a patient’s tumor and are not presented in healthy tissue, can be used to design various types of cancer therapies (e.g. cancer vaccines or CAR-T therapy). Thus, identifying peptides that are antigenic, common for several cancer types, and bound by several HLA haplotypes holds tremendous potential for the scientific community and pharmaceutical industries. Current efforts for antigen discovery focus on identifying peptides with tumor-specific genomic mutations, through profiling tumor immunopeptidome or with transcriptomic data, both combined with HLA binding predictions using computational tools. As these methods rely only on the encoded amino acid sequence of proteins, they overlook the realm of protein modifications (PTMs) on HLA-bound peptides. Post-translational processing and modifications such as phosphorylations, citrullinations, or glycosylations, have been shown to play a large part in modulating both peptide presentation and subsequent T-cell recognition. However, identifying modified peptides remains a challenge because the combinatorial analysis of PTMs increases the theoretical number of peptide possibilities tremendously.
Therefore, there is a need for a method that predicts cancer-specific modified HLA-bound peptides, which takes into account the unique PTM on these peptides.

The Solution

The Merbl lab developed a computational pipeline to detect endogenous peptides and their PTMs. The improved pipeline allows for the combinatorial detection of multiple PTMs at the same search, a task that is not feasible by currently available tools.

Technology Essence

The team developed PROMISE (PROtein Modification Integrated Search Engine), which enables efficient search against combinatorial reference data with multiple modifications. Compared to an existing search tool (MaxQuant), PROMISE decreased search time by 100-fold. Looking for insight into PTM-driven antigenicity, the team used PROMISE to analyze 29 different PTM combinations simultaneously in immunopeptidomics data obtained by patient tumors tissues, healthy adjacent tissues, cancer cell lines, and tumor-infiltrating lymphocytes (TILs) (Figure 1). The search expanded peptide identification by 22% and enriched the modified peptide fraction threefold, yielding hundreds of novel modified antigens derived from cancer-associated proteins and cancer-specific immunopeptide signatures. Importantly, the team further confirmed their results by in vitro and ex vivo assays, showing the identified cancer-associated modified peptides can bind to MHC, are immunogenic, and can stimulate CD8 T cell-mediated killing of tumor cells.

Applications and Advantages

  • Identifying novel cancer neoantigens for developing new anti-cancer treatments.
  • Identifies endogenous modified peptides at biological levels, which make it usable for clinical settings.
  • Additional human pathologies such as infections and autoimmunity

Development Status

The team fully developed PROMISE, a computational platform for identification of endogenous modified peptides.
By applying their platform tested on public HLA–profiling available data, new targets were identified, confirmed experimentally, and proved to induce anti-tumor immunological response in a murine model system.

Related Keywords

  • Biological Sciences
  • Medicine, Human Health
  • Medical Research
  • Biology / Biotechnology
  • Cellular and Molecular Biology Technology
  • Diagnostic

About Yeda

Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.

WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.

Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.

Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.

Yeda performs the following activities:

◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.

Our portfolio covers a broad spectrum of the natural sciences, including:

◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools

Yeda

Never miss an update from Yeda

Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide

Yeda

Send a request for information
to Yeda

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support